Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2106.85%.

  • Inhibrx Biosciences' EBITDA Margin rose 1587911500.0% to 2106.85% in Q2 2025 from the same period last year, while for Sep 2025 it was 11949.57%, marking a year-over-year increase of 61676900.0%. This contributed to the annual value of 165724.0% for FY2024, which is 1535450600.0% down from last year.
  • Per Inhibrx Biosciences' latest filing, its EBITDA Margin stood at 2106.85% for Q2 2025, which was up 1587911500.0% from 1595.43% recorded in Q1 2025.
  • In the past 5 years, Inhibrx Biosciences' EBITDA Margin ranged from a high of 1595.43% in Q1 2025 and a low of 160898.0% during Q2 2024
  • Moreover, its 3-year median value for EBITDA Margin was 21956.66% (2023), whereas its average is 49017.42%.
  • In the last 5 years, Inhibrx Biosciences' EBITDA Margin tumbled by -445247600bps in 2024 and then surged by 1587911500bps in 2025.
  • Inhibrx Biosciences' EBITDA Margin (Quarter) stood at 5403.24% in 2023, then tumbled by -824bps to 49928.0% in 2024, then surged by 96bps to 2106.85% in 2025.
  • Its last three reported values are 2106.85% in Q2 2025, 1595.43% for Q1 2025, and 49928.0% during Q4 2024.